F8 and hemophilia A: Hemophilia A mice were divided into two treatment groups (Figure 1 and Figure S1 in Supplementary Material): FVIII plasmid-treated mice were given anti-CD20 (250 μg/mouse) on days 0 and 14 combined with a FVIII plasmid (pBS-HCRHPI-FVIIIA; 50 μg/mouse) expressing B domain-deleted hFVIII under the control of the liver-specific hAAT promoter (HP) and the hepatic control region (HCR) on day 0.